Table 3.
Characteristics of published and unpublished trials
| |
|
OR |
|||||
|---|---|---|---|---|---|---|---|
| |
n | Published, % | Crude (95% CI) | p Value | Adjusted (95% CI) | p Value | |
| Sponsor type | Non-industry | 103 | 52, 49.51 | 1 | 1 | ||
| Industry | 44 | 27, 61.36 | 1.56 (0.76 to 3.20) | 0.227 | 2.03 (0.88 to 4.69) | 0.099 | |
| Phase | 1, 2 | 12 | 5, 41.67 | 0.74 (0.21 to 2.67) | 0.650 | 0.89 (0.24 to 3.33) | 0.860 |
| 2 | 49 | 24, 48.98 | 1 | 1 | – | ||
| 2, 3 | 6 | 5, 83.33 | 5.21 (0.57 to 47.90) | 0.145 | 5.13 (0.52 to 50.33) | 0.160 | |
| 3 | 26 | 12, 46.15 | 0.89 (0.34 to 2.32) | 0.816 | 0.68 (0.23 to 2.05) | 0.492 | |
| 4 | 14 | 9, 64.29 | 1.87 (0.55 to 6.40) | 0.316 | 2.10 (0.59 to 7.50) | 0.256 | |
| Not applicable | 40 | 24, 60.00 | 1.56 (0.67 to 3.64) | 0.301 | 1.95 (0.77 to 4.99) | 0.161 | |
| Sample size (quartiles) | First (4–52) | 34 | 17, 50.00 | 0.95 (0.38 to 2.38) | 0.910 | 1.07 (0.41 to 2.77) | 0.894 |
| Second (52–116) | 39 | 20, 51.28 | 1 | – | 1 | – | |
| Third (116–387) | 36 | 19, 52.78 | 1.06 (0.43 to 2.63) | 0.900 | 0.98 (0.36 to 2.64) | 0.969 | |
| Fourth (387–15 460) | 37 | 23, 62.16 | 1.56 (0.63 to 3.89 | 0.340 | 1.48 (0.51 to 4.31) | 0.474 | |